The move will enable the company to strengthen its foothold in the US and establish its presence in the fast-growing global biologics CDMO space.

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

Some of the biggest U.S. investment announcements from Europe so far have come from the pharmaceutical sector, with Swiss ...